Sun Pharma Advanced Research (NSE:SPARC, BOM:532872) narrowed its consolidated loss to 597.7 million Indian rupees in the fiscal fourth quarter ended March 31 from 1.06 billion rupees a year ago.
Loss per share fell to 1.84 rupees from 3.26 rupees, according to a Monday filing to the Indian stock exchanges by the biopharmaceutical company.
Revenue from operations in fiscal Q4 increased to 271.9 million rupees from 165.6 million rupees a year earlier.
The company's shares were down nearly 4% in recent trade.